FY26 HCD-W Coagulation Analyzer CPRR Consolidation Effort

SOL #: HT941026Q2004Consolidate Bundle

Overview

Buyer

DEPT OF DEFENSE
Defense Health Agency (Dha)
DEFENSE HEALTH AGENCY HCD WEST
CAMP PENDLETON, CA, 92055, United States

Place of Performance

Place of performance not available

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

PSC

In Vitro Diagnostic Substances, Reagents, Test Kits And Sets (6550)

Set Aside

No set aside specified

Timeline

1
Posted
Jan 22, 2026
2
Last Updated
May 20, 2026

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Health Agency (DHA) Healthcare Contracting Division - West (HCD-W) is soliciting proposals for a Cost Per Reportable Result (CPRR) contract for Coagulation analyzers to support military treatment facilities (MTFs) across HCD-W. This is a consolidated, unrestricted acquisition for a single award contract. The requirement includes analyzers, reagents, supplies, maintenance, and training. Proposals are due April 30, 2026.

Purpose & Scope

This opportunity aims to consolidate existing coagulation analyzer requirements from twenty-four MTFs into a single Firm-Fixed-Price (FFP) contract. The CPRR model covers all reagents, standards, quality controls, supplies, consumables, analyzer equipment, parts, peripherals (e.g., printers, UPS units), and all services necessary for coagulation analysis/testing, preventive maintenance, and repairs. The objective is to achieve cost savings, improve quality, and reduce acquisition cycle times through standardization.

Key Requirements

  • Equipment: New, FDA-approved coagulation analyzers capable of bidirectional interface with existing electronic health records (EHR) and Military Healthcare System (MHS) Genesis. Must support up to a 50% surge in volume and operate without third-party reagents. Title to equipment remains with the Contractor.
  • Maintenance & Support: Comprehensive maintenance (preventive and repair) to ensure a minimum 95% uptime rate for all analyzers at each MTF. Includes 2-hour callback for technical assistance, 24-hour on-site service for routine repairs, and equipment repair within 48 hours. Continuously stocked inventory of consumable supplies and emergency supply delivery within 24 hours.
  • Training: User-level training for core staff (up to 10 users) and advanced super-user training for government personnel.
  • Data & Reporting: Monthly reports for invoicing, detailing actual test quantities. Data must be accessible for external analysis and download in an ODBC-compliant format. Compliance with DoD Cybersecurity/Risk Management Framework (RMF) requirements is mandatory, including completion of a Medical Device and Equipment Risk Assessment (MDERA) Questionnaire.
  • Environmental: Description of hazardous waste characteristics and disposal procedures according to CFR Title 40. Onboard environmental sensors to mitigate hazards.

Period & Place of Performance

  • Duration: One base year and four option years, plus a 6-month extension. Total potential period of up to five years and six months.
  • Locations: Multiple MTFs across HCD-W, including Naval Hospital Bremerton, Naval Hospital Camp Pendleton, Madigan Army Medical Center, Naval Medical Center San Diego, Tripler Army Medical Center, and others. The government reserves the right to add additional MTFs.
  • Installation Deadline: All analyzers must be functioning and live by October 1, 2027.

Contract Details

  • Contract Type: Firm-Fixed-Price (FFP) CPRR.
  • Set-Aside: Unrestricted (Full and Open Competition).
  • NAICS Code: 334516 – Analytical Laboratory Instrument Manufacturing (Size Standard: 1000 employees).
  • PSC: 6550 – In Vitro Diagnostic Substances, Reagents, Test Kits And Sets.

Submission & Evaluation

  • Submission Deadline: Quotations must be received no later than 1:00 p.m. Pacific on Monday, April 30, 2026.
  • Submission Method: Electronic submission via email to bobbie.s.dobberstein.ctr@health.mil and cha-on.p.gordon2.civ@health.mil.
  • Questions Deadline: Questions must be submitted via email by 1:00 p.m. Pacific on Wednesday, April 8, 2026.
  • Evaluation Factors: Award will be made on a "Best Value Tradeoff" basis, considering:
    1. Technical (Factor 1)
    2. Past Performance (Factor 2)
    3. Information Assurance (Factor 3)
    4. Price (Factor 4) Factors 1 and 2 are approximately equal and combined are more important than Factor 3. Factors 1, 2, and 3 combined are more important than Factor 4 (Price). Unacceptable ratings in Technical or Information Assurance, or Limited/No Confidence in Past Performance, will lead to disqualification.

Contact Information

People

Points of Contact

Files

Files

Download
Download
Download
Download
Download
Download
Download
Download
Download
Download

Versions

Version 9
Combined Synopsis/Solicitation
Posted: May 20, 2026
View
Version 8
Combined Synopsis/Solicitation
Posted: May 19, 2026
View
Version 7Viewing
Consolidate Bundle
Posted: May 11, 2026
Version 6
Solicitation
Posted: Apr 30, 2026
View
Version 5
Solicitation
Posted: Apr 23, 2026
View
Version 4
Solicitation
Posted: Mar 24, 2026
View
Version 3
Pre-Solicitation
Posted: Jan 26, 2026
View
Version 2
Pre-Solicitation
Posted: Jan 26, 2026
View
Version 1
Pre-Solicitation
Posted: Jan 22, 2026
View